

HARMONi-7 Phase 3 Clinical Trial

Phase 3 Study in 1L Metastatic NSCLC with High PD-L1 Expression (NCT06767514)¹


Ivonescimab:

Most Advanced PD-1/VEGF Bispecific Antibody in Clinical Development in the U.S. and EU.* Brings two validated mechanisms in oncology²⁻⁴ into ONE novel tetravalent molecule.

Ivonescimab simultaneously blocks both PD-1 & VEGF


Globally 2,300+ patients have been treated with ivonescimab across Summit and Akeso clinical trials.⁵ Summit is actively recruiting approximately 780 patients worldwide for the HARMONi-7 study.

HARMONi-7



HARMONi-7 STUDY DESIGN

Monotherapy Ivonescimab vs. Pembrolizumab



KEY ELIGIBILITY CRITERIA

- Metastatic (Stage IV) NSCLC, PD-1 $\geq 50\%$
- ECOG 0 or 1
- Histologically or cytologically confirmed squamous or non-squamous NSCLC. No histologic or cytopathologic evidence of the presence of small cell lung carcinoma
- Patients' tumor must have high PD-L1 expression
- No prior systemic treatment for metastatic NSCLC
- No known actionable genomic alterations in EGFR, ALK, ROS1 or BRAF V600E for which first-line approved therapies are available
- No radiologically documented evidence of major blood vessel invasion, or tumor invading organs, or major blood vessel encasement with narrowing of the vessel or intratumor lung cavitation or necrosis that the investigator determines will pose a significantly increased risk of bleeding
- No symptomatic CNS metastases or CNS metastases with hemorrhagic features or CNS metastases ≥ 1.5 cm
- No history of bleeding tendencies or coagulopathy and/or clinically significant bleeding symptoms or risk within 4 weeks

Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China's National Medical Products Administration (NMPA).

*There are no known PD-1-based bispecific antibodies approved by the U.S. Food and Drug Administration ("FDA") or the European Medicines Agency ("EMA").

Abbreviations: ALK=anaplastic lymphoma kinase; CNS=central nervous system; DCR=disease control rate; DOR=duration of response; ECOG=eastern cooperative oncology group; EGFR=epidermal growth factor receptor; IRRC=independent radiologic review committee; NSCLC=non-small cell lung cancer; ORR=overall response rate; OS=overall survival; PD-1=programmed cell death protein 1; PFS=progression-free survival; PK=pharmacokinetics; Q3W=every 3 weeks; VEGF=vascular endothelial growth factor.

By use of this QR Code you agree to Summit's privacy notice located at smttx.com.



Ivonescimab: Designed to Potentially Improve the Balance of Anti-tumor Activity & Safety⁶⁻⁸

Brings two validated mechanisms in oncology²⁻⁴ into ONE novel tetravalent molecule

Cooperative Binding⁸

Cooperative Binding Offers the Potential to Drive Synergistic Anti-tumor Activity

Increased Avidity in the Tumor Microenvironment (TME)^{8*}

VEGF increases affinity to **PD-1** by **>18X**

PD-1 increases affinity to **VEGF** by **>4X**


Multimeric Complexes of Ivonescimab^{8*}

VEGF dimerization brings together ivonescimab molecules that bind to each other which may improve T-cell engagement


T ½ 6-7 Days and Fc-null Region⁸

Could potentially lead to a favorable safety profile^{6,7}


**in vitro*



Tumor Microenvironment



Tumor Microenvironment with Ivonescimab Cooperative Binding



Images for illustrative purposes only

● VEGF Dimer Y PD-1 Receptor in T Cell

Ivonescimab is an investigational therapy that is not presently approved by any regulatory authority other than China's National Medical Products Administration (NMPA).

Summit Contact: medinfo@smmttx.com

1. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 ClinicalTrials.gov identifier: NCT06767514. Updated Jan 10, 2025, Accessed on Jan. 10, 2025.; 2. Manegold C, et al. J Thorac Oncol 2017;12(2):194-207.; 3. Pardoll, D. Nat Rev Cancer 2012;12(4):252-64.; 4. Tamura R, et al. Med Oncol 2020;37(1):2.; 5. Data on File.; 6. Zhao Y, et al., eClinicalMedicine. 2023; 3(62): 102106.; 7. Wang L, et al. J Thorac Oncol. 2024 Mar;19(3):465-475; 8. Zhong T, et al. AACR-NCI-EORTC International Conference 2023. Poster #B123, Abstract #35333, Boston, MA, USA.